Placebo Neuroepo multisession Phase II and III
A randomized, placebo-controlled clinical trial investigating the neuroprotective and neuromodulatory effects of intranasal NeuroEPO (erythropoietin) in Parkinson's disease patients. The study combines clinical assessments using the MDS-UPDRS III scale with EEG recordings at baseline and 9-month post-intervention timepoints to evaluate whether NeuroEPO-induced changes in brain function, as measured by EEG source activity, mediate cognitive and motor outcomes. This multisession Phase II/III dataset provides evidence for EPO's role in synaptic plasticity and dopaminergic system resilience.
- Participants
- 24
- Channels
- 19 (10-20)
- Size
- 271 MB
- Version
- v1.0.0
- Updated
- Jul 22, 2026